Table 2.
Characteristics of pancreatic gastrointestinal stromal tumours: a summary of 18 cases
| Age (years) | Range: 31−74 | Mean: 52 | Median: 53 |
|---|---|---|---|
| Gender | Female: 55% (10/18) | Male: 45% (8/18) | |
| Presentation | Asymptomatic | Weakness | Weight loss |
| Abdominal pain | Fatigue | Nausea | |
| Emesis | Gastrointestinal bleed | Back pain | |
| Palpable mass | Anaemia (33%, 6/18) | ||
| Location | Pancreatic head: 50% (9/18) | Pancreatic body/tail: 50% (9/18) | |
| Tumour size (cm) | Range: 2–30 | Mean: 12 | Median: 10.5 |
| Mitoses (per 50 HPF) | Range: 1–120 | Mean: 14.8 | Median: 7 |
| Risk assessment | High: 88% (15/17) | Intermediate: 12% (2/17) | |
| Histology | CD117: 100% (17/17) | CD34: 77% (10/13) | |
| Preoperative dx | 22% (4/18) | ||
| Surgical therapy | Whipple: 53% (8/15) | Distal pan: 40% (6/15) | Cystej: 7% (1/15) |
| Medical therapy | Imatinib: 54% (7/13) | Sunatinib: 8% (1/13) | |
| Outcome | Follow-up: 5 month–5 year Recurrence: 17% (2/12 mets: 25% (3/12) | ||